Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Laurie McWilliams

Allergy & Immunology Raleigh, NC Medical Doctor

NPI 1699942714 CMS profile 781687

2615 Lake Dr, Suite 301, Raleigh, NC 27607

Open in the dashboard

General payments

$84,762

376 records reported · program years 2019–2025

Research payments

$3,555

Paid to them · 4 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$70,202 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Laurie McWilliams of Raleigh, NC is reported in the CMS Open Payments database as having received $84,762 across 376 general payments and $3,555 in research payments paid to them. Separately, studies naming them as principal investigator received $70,202 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,251 110
2025 Research $2,397 2
2024 General $14,891 72
2024 Research $1,158 2
2023 General $11,055 55
2022 General $15,643 42
2021 General $15,660 26
2020 General $9,237 14
2019 General $8,026 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laurie McWilliams
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Laurie McWilliams were reported at $10,251. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Laurie McWilliams Allergy & Immunology median Middle half National median
2019 $8,026 $594 $163–$1,512 $163
2020 $9,237 $426 $106–$1,233 $114
2021 $15,660 $638 $157–$1,708 $132
2022 $15,643 $790 $205–$1,961 $149
2023 $11,055 $852 $220–$2,147 $160
2024 $14,891 $865 $203–$2,267 $164
2025 $10,251 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $56,939 80 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $10,219 11 payments
  3. Chiesi USA, Inc. $8,070 8 payments
  4. AstraZeneca Pharmaceuticals LP $3,071 34 payments
  5. Genentech USA, Inc. $1,494 9 payments
  6. Regeneron Healthcare Solutions, Inc. $1,046 49 payments
  7. Amgen Inc. $821 83 payments
  8. Genzyme Corporation $679 23 payments
  9. Novartis Pharmaceuticals Corporation $289 8 payments
  10. Grifols USA, LLC $232 6 payments
  11. Other $1,902 65 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $64,230 35 payments
  2. Food and Beverage $8,968 315 payments
  3. Consulting Fee $7,174 7 payments
  4. Travel and Lodging $3,939 11 payments
  5. Education $276 7 payments
  6. Honoraria $175 1 payment
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $28,023 31 payments
  2. AREXVY $10,993 8 payments
  3. TEZSPIRE Respiratory $2,292 8 payments
  4. FASENRA $2,149 8 payments
  5. AIRSUPRA $1,626 7 payments
  6. Xolair $1,582 10 payments
  7. DUPIXENT Immunology $911 26 payments
  8. TEZSPIRE Inflammation $744 80 payments
  9. DUPIXENT Inflammation And Immunology $729 28 payments
  10. DUPIXENT Immunology And Inflammation $317 21 payments
  11. Other $3,120 133 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $3,555 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

533

Median for Allergy/ Immunology: 449

Drug cost

$365,028

Median for Allergy/ Immunology: $169,700

Branded share of claims

61.9%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 12 $101,331
Dupixent Syringe Dupilumab Brand 17 $99,971
Dupixent Pen Dupilumab Brand 14 $49,497
Xolair Omalizumab Brand 11 $31,058
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 24 $17,916
Advair Hfa Fluticasone Propion/Salmeterol Brand 31 $13,170
Spiriva Respimat Tiotropium Bromide Brand 12 $9,724
Symbicort Budesonide/Formoterol Fumarate Brand 36 $8,862
Epinephrine Generic 25 $6,374
Arnuity Ellipta Fluticasone Furoate Brand 23 $5,352

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$281,581

Of which drugs: $248,019

Medicare patients

185

Average age 73

Services billed

11,951

141 women, 44 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 44%
Depression 19%
Osteoporosis 17%
Ischemic heart disease 15%
Diabetes 14%
Cancer 14%
Chronic kidney disease 10%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, omalizumab, 5 mg J2357 Office 11 3,270 $97,512

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AREXVY
  • GlaxoSmithKline, LLC. $10,967
$10,967 — —
DUPIXENT
  • GENZYME CORPORATION $377
  • Regeneron Healthcare Solutions, Inc. $194
  • SANOFI-AVENTIS U.S. LLC $100
$671 31 —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $223
  • Amgen Inc. $177
$399 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $264
$264 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $223
$223 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

380 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record